Eldridge Investment Advisors’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.4M | Sell |
9,540
-23
| -0.2% | -$4.95K | 0.48% | 38 |
|
|
2026
Q1 | $2.08M | Buy |
9,563
+3
| +0% | +$665 | 0.46% | 44 |
|
|
2025
Q4 | $2.18M | Sell |
9,560
-201
| -2% | -$45.8K | 0.48% | 38 |
|
|
2025
Q3 | $2.26M | Buy |
9,761
+4
| +0% | +$815 | 0.51% | 37 |
|
|
2025
Q2 | $1.81M | Buy |
9,757
+524
| +6% | +$97.4K | 0.38% | 53 |
|
|
2025
Q1 | $1.93M | Buy |
9,233
+5
| +0.1% | +$972 | 0.45% | 51 |
|
|
2024
Q4 | $1.64M | Sell |
9,228
-409
| -4% | -$75.2K | 0.38% | 58 |
|
|
2024
Q3 | $1.9M | Buy |
9,637
+4
| +0% | +$747 | 0.45% | 52 |
|
|
2024
Q2 | $1.65M | Buy |
9,633
+609
| +7% | +$101K | 0.42% | 56 |
|
|
2024
Q1 | $1.64M | Buy |
9,024
+33
| +0.4% | +$5.69K | 0.42% | 57 |
|
|
2023
Q4 | $1.39M | Sell |
8,991
-95
| -1% | -$13.8K | 0.36% | 62 |
|
|
2023
Q3 | $1.35M | Buy |
9,086
+4
| +0% | +$587 | 0.45% | 45 |
|
|
2023
Q2 | $1.22M | Sell |
9,082
-85
| -0.9% | -$12.5K | 0.4% | 50 |
|
|
2023
Q1 | $1.46M | Buy |
9,167
+5
| +0.1% | +$764 | 0.51% | 44 |
|
|
2022
Q4 | $1.48M | Sell |
9,162
-8
| -0.1% | -$1.23K | 0.52% | 43 |
|
|
2022
Q3 | $1.23M | Buy |
9,170
+445
| +5% | +$63.9K | 0.48% | 42 |
|
|
2022
Q2 | $1.34M | Buy |
8,725
+4
| +0% | +$611 | 0.5% | 38 |
|
|
2022
Q1 | $1.41M | Sell |
8,721
-39
| -0.4% | -$5.67K | 0.48% | 38 |
|
|
2021
Q4 | $1.19M | Buy |
8,760
+5
| +0.1% | +$591 | 0.39% | 41 |
|
|
2021
Q3 | $944K | Buy |
8,755
+5
| +0.1% | +$571 | 0.34% | 48 |
|
|
2021
Q2 | $986K | Buy |
8,750
+4
| +0% | +$450 | 0.36% | 48 |
|
|
2021
Q1 | $946K | Buy |
8,746
+5
| +0.1% | +$535 | 0.37% | 45 |
|
|
2020
Q4 | $937K | Buy |
8,741
+5
| +0.1% | +$480 | 0.39% | 41 |
|
|
2020
Q3 | $765K | Buy |
8,736
+3
| +0% | +$282 | 0.36% | 41 |
|
|
2020
Q2 | $857K | Buy |
8,733
+8
| +0.1% | +$704 | 0.43% | 32 |
|
|
2020
Q1 | $665K | Buy |
8,725
+5
| +0.1% | +$426 | 0.38% | 37 |
|
|
2019
Q4 | $772K | Buy |
8,720
+4
| +0% | +$332 | 0.38% | 44 |
|
|
2019
Q3 | $660K | Buy |
8,716
+7
| +0.1% | +$480 | 0.34% | 44 |
|
|
2019
Q2 | $633K | Buy |
8,709
+48
| +0.6% | +$3.77K | 0.34% | 42 |
|
|
2019
Q1 | $698K | Buy |
8,661
+5
| +0.1% | +$409 | 0.38% | 41 |
|
|
2018
Q4 | $798K | Buy |
+8,656
| New | +$761K | 0.49% | 32 |
|
Other funds holding ABBV
Eldridge Investment Advisors's ABBV Position: Q2 2026 in Review
Eldridge Investment Advisors reduced its AbbVie (ABBV) stake by 0.24% in Q2 2026, selling an estimated $4.95K and leaving 9,540 shares worth $2.4M. The position accounts for 0.48% of the portfolio, ranked #38.
Eldridge Investment Advisors first reported a position in ABBV in Q4 2018 and has held it in 31 quarters since. 4,224 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Eldridge Investment Advisors held 9,540 shares of AbbVie worth $2.4M as of Q2 2026.
- Eldridge Investment Advisors sold 23 AbbVie shares in Q2 2026, an estimated $4.95K.
- AbbVie made up 0.48% of Eldridge Investment Advisors's portfolio in Q2 2026, its #38 holding.
- Eldridge Investment Advisors first reported a position in AbbVie in Q4 2018 and has held it in 31 quarters since.
- 4,224 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Eldridge Investment Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.